EXREnu™ Human Serum-Free NK Cell Expansion Kit
$489.00
Out of stock
Categories: Cell Culture, NK Cell Media
SKU: EXCM007
In-stock products will arrive in 1 to 2 business days.
For Research Use Only.
Not Intended for Diagnostic or Therapeutic Use.
Key Features
✓ Chemically defined
✓ Animal component-free
✓ Batch stability
✓ Optimized for high yield and purity of NK cells
✓ Includes NK cell stimulator and activator reagents
Size
✓ 1L/Kit
Need Help Ordering?
Product Details
Storage & Preparation
Data Images
Background
Product Documents
Product Details
| Product Type | Cell Culture Media, NK Cell Expansion Kit |
| Product Summary |
|
| Reactivity | Expansion of human peripheral blood mononuclear cells (PBMCs)
|
| Product Components |
|
Storage & Preparation
| Shipping |
|
| Stability & Storage |
|
Data Images

Fig A. After 14 days of culture, the population of CD3-CD56+ NK cells was between 60 to 95%.

Fig B. After 14 days of culture, 4 billion cells were harvested per 1L Amplification Media using the EXREnu™ Human
NK Cell Expansion Kit. The typical expansion using this kit is 80 to 180-fold.
Background
| Alternative Names | Natural Killer Cells, NK Cells, Large Granular Lymphocytes, LGL, CD56+/CD3– cells |
| Function | Natural killer (NK) cells are lymphocytes characterized by the absence of CD3 with high levels of CD56/NCAM-1. NK cells eliminate tumor and virus-infected cells within the innate immune response through the release of perforin and granzymes, while secreting cytokines and chemokines to modulate additional immune cell populations. The innate anti-tumor response of NK cells and potential shift away from autologous immune cell therapies make NK cells an attractive candidate for therapeutic research and development. |
Product Documents
| Product Datasheet | Download Product Datasheet |
| COA | Contact Us |
| SDS | Download SDS |
You may also be interested in related products:
Reviews (no reviews yet)
Only logged in customers who have purchased this product may leave a review.



Reviews
There are no reviews yet.